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Melanoma is the leading cause of death from skin cancer in industrialized countries. Several melanoma-related
biomarkers and signaling pathways have been identified; however, their relevance to melanoma development/
progression or to clinical outcome remains to be established. Aberrant activation ofWnt/β-catenin pathway is implicated
in various cancers includingmelanoma.Wehavepreviously demonstratedRad6, anubiquitin-conjugatingenzyme, as an
important mediator of β-catenin stability in breast cancer cells. Similar to breast cancer, β-catenin-activating mutations
are rare inmelanomas, and since β-catenin signaling is implicated inmelanoma, we examined the relationship between
β-catenin levels/activity and expression of β-catenin transcriptional targets Rad6 and microphthalmia-associated
transcription factor-M (Mitf-M) in melanoma cell models, and expression of Rad6, β-catenin, and Melan-A in nevi and
cutaneous melanoma tissue specimens. Our data show that Rad6 is only weakly expressed in normal human
melanocytes but is overexpressed in melanoma lines. Unlike Mitf-M, Rad6 overexpression in melanoma lines is
positively associated with high molecular weight β-catenin protein levels and β-catenin transcriptional activity. Double-
immunofluorescence staining of Rad6 and Melan-A in melanoma tissue microarray showed that histological diagnosis
of melanoma is significantly associated with Rad6/Melan-A dual positivity in themelanoma group compared to the nevi
group (P = .0029). In contrast to strong β-catenin expression in normal and tumor areas of superficial spreading
malignant melanoma (SSMM), Rad6 expression is undetectable in normal areas and Rad6 expression increases
coincidewith increasedMelan-A in the transformed regions of SSMM. These data suggest a role for Rad6 inmelanoma
pathogenesis and that Rad6 expression status may serve as an early marker for melanoma development.
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Melanoma is the leading cause of death from skin cancer in
industrialized countries. Numerous potential biomarkers have been
identified by high throughput technologies; however, their relevance
to melanoma development, progression, or clinical outcome remains
to be established [1]. Currently used histological criteria such as
primary tumor invasion and lymph node status fail to identify early-
stage disease and cases that will eventually progress. Thus, there is a
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melanoma, predict melanoma progression, or identify patients with
subclinical metastatic disease. While several biomarkers identified
previously (e.g., p53, c-myc, CD44, and bcl-2) have shown limited
clinical utility, others have potential prognostic significance and
include microphthalmia-associated transcription factor (Mitf), p16,
β-catenin, tissue plasminogen activator, and ephrin A1 among others
[1, and references within].
β-Catenin functions as a structural protein to regulate cell adhesion
via interactions with E-cadherin, and is also involved in activation of the
canonical Wnt signaling pathway. Aberrant activation of Wnt/β-
catenin pathway results from β-catenin accumulation and is implicated
in development and progression of various cancers including colon
cancer, breast cancer, prostate cancer, esophageal cancer, andmelanoma
[2]. Levels of β–catenin are kept low through amultiprotein APC/Axin/
β-TrCP-regulated 26S proteasomal degradation system [3–6]. Howev-
er, overexpression of certainWnt ligands, loss ofWnt inhibitory factors,
or mutations in key components of the multiprotein β-catenin
degradation complex contribute to accumulation of β-catenin and
activation of the canonical Wnt signaling pathway [2]. Aberrant
accumulation of β-catenin in the cytoplasm/nucleus is correlated
with poor prognosis for several cancer types [2,7].
Nearly one-third of human primary melanoma specimens and
melanoma cell lines have been reported to display β-catenin accumulation
[8,9], implying a significant functional role for the Wnt/β-catenin
pathway in human melanoma. Much of the tumor promoting effects of
β-catenin arise from its function as a transcription factor in complex with
T-cell factor or LEF-1 (lymphocyte enhancer factor 1) proteins to activate
its target genes involved in tumorigenesis such as c-myc [10], Mitf [11],
and cyclin D1 [12]. Mitf, a basic/helix-loop–helix/leucine-zipper
transcription factor [13] was first identified in mouse, mutation of
which results in loss of pigmentation [14]. Mitf exists in multiple
isoforms (Mitf-A,Mitf-B,Mitf-C,Mitf-D,Mitf-H andMitf-M) that are
expressed from distinct promoters [15] and yield different expression
profiles. The Mitf-M isoform is melanocyte-specific and functions in
melanocyte differentiation and survival [16]. Functional studies place
Mitf as an essential lineage-specific target of Wnt/β-catenin signaling
both inmelanocyte development, andmelanoma tumorigenesis [11,17].
Previous studies from our laboratory demonstrated Rad6B, an
ubiquitin conjugating enzyme and a key component of the
postreplication DNA repair pathway [18–23], and as an important
mediator of β-catenin stability in breast cancer cells [24]. Rad6B
enhances β-catenin stability and transcriptional activity by inducing
lysine 63-linked polyubiquitin modifications in β-catenin that render
β-catenin insensitive to 26S proteasomal degradation [24]. Rad6B is
also a transcriptional target of β-catenin [25], thus activating a
positive feedback loop between β-catenin-induced Rad6B gene
expression and Rad6-induced β-catenin stabilization [24–26]. Rad6
expression is low in normal breast tissues, and increases in Rad6
expression become detectable in early breast cancer with continued
overexpression in invasive breast carcinomas and metastatic breast
cancer [27,28]. As in breast cancer [29], β-catenin activating
mutations are rare in melanomas [9], and since β-catenin signaling
is implicated in melanoma development and progression, we
examined the relationship between Rad6, Mitf, and β-catenin levels/
activity in melanoma cell models, and expression of Rad6 in nevi and
cutaneous melanomas. Our data show that Rad6 is only weakly
expressed in normal human epidermal melanocytes, but is over-
expressed in melanoma lines, and unlike Mitf-M, Rad6 expressioncorrelates with elevated levels of highmolecular weight β-catenin and β-
catenin transcriptional activity. Immunofluorescence analysis of Rad6
andMelan-A in melanoma tissue microarray showed weak or low Rad6
expression in nevi compared to malignant melanomas. Furthermore,
while Rad6 expression is negligible in normal areas of skin, increases in
Rad6 expression coinciding with increases in Melan-A positive cells are
observed in superficial spreading malignant melanoma (SSMM),
suggesting that Rad6 expression status could serve as an early marker
of neoplastic conversion to melanoma.
Materials and Methods
Cell Culture
Normal human primary epidermal melanocytes (HeMa-LP; (Life
Technologies, Carlsbad, California) were cultured in Dermal Cell Basal
Medium supplemented with melanocyte growth supplements insulin
(5 μg/ml), ascorbic acid (50 μg/ml), L-glutamine (6 mmol/L), epineph-
rine (1.0 μmol/L), calcium chloride (0.2 mmol/L) and M8 supplement
(ATCC, Manassas, VA). Cultures were used within 5 to 10 passages.
Human melanoma cell lines A2058 (ATCC), A375 (ATCC), MelJuso
(DSMZ, Braunschweig, Germany), M14 (National Cancer Institute,
Frederick, Maryland), Malme-3 M and G361 (ATCC) were cultured in
RPMI 1640 medium with 10% fetal bovine serum. The human breast
cancer cell line MDA-MB-231 cells (ATCC) were maintained in
DMEM/F12 medium supplemented with 5% fetal bovine serum [30].
Migration and Invasion Assays
Migration/invasion assays were performed in Boyden chambers
(Neuroprobe, Cabin John, MD) containing 8 μm pore size polycarbon-
ate membrane coated with Matrigel basement membrane matrix (BD
Biocoat, BD Biosciences, Bedford, MA) as described previously [30].
100 × 103 Cells in serum-free media were seeded in transwell
chambers and following incubation overnight at 37°C and 5% CO2,
the migrated/invaded cells were fixed and counted after staining with
Protocol Hema 3 stain set (Fisher Scientific, Pittsburgh, PA). Stained
membranes were scanned and density of spots quantitated with NIH
Imaging J Version 1.62. Assays were performed in sextuplets.
Western blot Analysis
Whole cell lysates were prepared as previously described [24].
Nuclear and cytoplasmic subfractions were prepared using a nuclear/
cytosol fractionation kit (MBL International, Woburn, MA).
Aliquots of whole cell lysates, nuclear, or cytoplasmic fractions
containing 25 μg protein were subjected to SDS-PAGE and western
blot analysis with antibodies to Rad6, β-catenin (SantaCruz
Biotechnology, Inc., Dallas, TX), β-actin (Sigma-Aldrich, St. Louis,
MO), MITF (clone C5, Abcam, Cambridge, MA), lamin A/C
(SantaCruz), or GAPDH (SantaCruz). In humans, the yeast
homologous Rad6 gene is duplicated and the proteins are encoded
by two genes HHR6A (or Rad6A) and HHR6B (Rad6B) from
chromosomes Xq24-q25 and 5q23-q31, respectively. Rad6A and
Rad6B share 95% identical amino acid residues [31], and the Rad6
antibody is unable to distinguish between Rad6A and Rad6B proteins
[27]. Therefore, rather than referring to the protein detected by the
antibody as Rad6A or Rad6B, we refer to it as Rad6.
Luciferase Reporter Assay
Melanoma and normal melanocytes (300 × 103 cells) were seeded
in 35 mm dishes and grown overnight. Cells were transfected with
TOP/Flash or FOP/Flash vectors (1.0 μg) and pSV40-Renilla
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were lysed with Passive lysis buffer (Promega, Madison, WI), and
firefly and Renilla luciferase activities measured using the Dual
Luciferase reporter assay kit (Promega). RLU firefly values from FOP/
Flash and TOP/Flash transfections were normalized against Renilla
luciferase and protein content.
Melanoma Tissue Array and Skin Specimen Analysis
The melanoma tissue microarray ME1004 (contains 24 and 56
cases of nevi and malignant melanoma, respectively; US Biomax Inc.,
Rockville, MD) was used to assess potential differences in Rad6
expression between benign and malignant melanocytic tumors. We
analyzed the first nine sequential primary melanomas and the first
nine sequential nevi in the tissue microarray that closely corresponded
to the anatomical sites of the melanoma tumors. We selected common
cutaneous melanomas, and excluded rare forms of melanoma in the
mucosa, genitalia or on volar surfaces. In addition, six cases of superficial
spreading cutaneous melanoma were retrieved from the files of the
Pinkus Dermatopathology Laboratory, a private dermatopathology
laboratory located in Monroe, Michigan. Preserved paraffin-embedded
tissue specimens collected for each case were assigned an accession code
that excluded patient identifier information. These non-identifiable
archived tumor samples were acquired after review and approval by the
Wayne State University Human Investigation Committee.
Immunofluorescence Analysis
HeMa-LP and melanoma cells were fixed with buffered formalin,
and permeabilized with methanol/acetone prior to incubation with
Rad6 and β-catenin antibodies [24]. Expression of Rad6, Melan-A, or
β-catenin was analyzed in melanoma tissue microarray ME1004, and
in clinical superficial spreading melanoma. Tissues were deparaffi-
nized, rehydrated, and boiled in 1 mmol/L sodium citrate buffer
(pH 6.0) by microwave for 10 minutes and blocked with Super
Block (Skytek Laboratories, Logan, UT) for 1 hour at room
temperature. Following incubation with the primary antibodies,
slides were incubated with FITC- or Texas Red-labeled secondary
antibodies (Molecular Probes), and nuclei counterstained with 4’,6-
diamidino-2-phenylindole (DAPI). Slides were also stained in the
absence of primary antibody or with isotype matched nonimmune
IgG to assess nonspecific reactions. Images were collected on an
Olympus BX60 microscope equipped with a Sony DXC-979 MD
3CCD video camera. Results were evaluated by two investigators in
blinded manner. Melanocytic and melanoma cells were identified
with Melan-A (MART-1) marker, and Rad6 staining in the tissues
was evaluated as a percentage of Melan-A stained cells in each section.
The histologic morphology of the tissue cores were confirmed by
counterstaining the slides with hematoxylin.Figure 1. Rad6 and high molecular weight β-catenin forms are
upregulated in melanoma lines. (A) Western blot analysis of Rad6
and β-catenin. High molecular weight species of β-catenin are
indicated by a bracket. (B) transcriptional activity of β-catenin.
Luciferase activity from TOP/Flash and FOP/Flash vectors were
normalized against Renilla luciferase. Columns, mean of four
independent experiments; bars, S.E. (P b .0001). (C) migration/
invasion of the indicated cell models measured by Boyden
chamber assay. Metastatic MDA-MB-231 breast cancer cells
were included as a positive control. Results are expressed as
mean ± S.E (P b .001) of replicate assays conducted in sextuplets.Statistical Analysis
Statistical analyses were performed with Student's t test and P values
b0.05 were considered statistically significant. To compare the number
of immunostained cells in nevi and melanoma, a two sample-2-sided t
test was utilized. Poisson regression model was employed with SAS
version 9 to analyze the association between histological diagnosis
(melanoma versus nevi) and occurrence of dual (Rad6 and Melan-A)
positive cells among Melan-A positive cell populations. The number of
Melan-A positive cells was used as an off-set variable, while the number
of Rad6 positive cells among them was used as a response variable, and
histological diagnosis as an explanatory variable.Results
Rad6 and β-Catenin are Co-Upregulated in Melanoma lines
Whereas several reports have linked increased expression of β-
catenin and activity with melanoma development and progression
[9,32–36], others have found correlation between elevated β-catenin
levels and improved survival of patients [37,38]. We have previously
reported that Rad6 overexpression induces polyubiquitin modifica-
tions of β-catenin that render it insensitive to 26S proteasomal
degradation and confer increased transcriptional activity [24].
Western blot analysis of whole cell lysates prepared from normal
human primary epidermal melanocytes (HeMa-LP cells) and a panel
of primary (MelJuso, A375, G361) and metastatic (A2058, M14)
melanoma lines for Rad6 expression showed substantially higher
Rad6 levels in A2058, MelJuso, G361 and M14 melanoma lines
compared to Malme-3 M and A375 cells, whereas it was negligible in
normal HeMa-LP melanocytes (Figure 1A). Simultaneous analysis of
β-catenin in the lysates showed 6 to 10-fold higher levels of high
Translational Oncology Vol. 7, No. 3, 2014 Rad6 Role in Melanoma Pathogenesis Rosner et al. 387molecular weight forms of β-catenin in MelJuso, G361, M14 and
A2058 cells compared to HeMa-LP cells (Figure 1A). A375 and
Malme-3 M cells expressed ~1.5- to 2-fold higher levels of high
molecular weight β-catenin compared to HeMa-LP cells (Figure 1A).
Levels of the nascent 97 kDa β-catenin protein were similar or only
marginally (1.5-fold) higher in melanoma cells compared to normal
HeMa-LP melanocytes. These data show a positive association
between Rad6 and modified β-catenin protein levels (Figure 1A). We
next performed TOP/FOP Flash reporter assays to determine
whether the increased levels of high molecular weight or modified
forms of β-catenin protein in melanoma cell lines translate into higher
β-catenin transcriptional activity. A2058 cells showed N100-fold
higher TOP/Flash activity compared to normal HeMa-LP cells, and
MelJuso, M14 and G361 lines showed N10-fold higher levels of
TOP/Flash activity compared to HeMa-LP, Malme-3 and A375 cells
(P b .0001; Figure 1B). These data suggest that melanoma lines
expressing high molecular weight β-catenin have transcriptionally
active β-catenin. Since canonical Wnt signaling is implicated in
migration of melanocytes, we assessed the migratory/invasiveFigure 2. Expression of Rad6, β-catenin and Mitf proteins in melanom
cytoplasmic and nuclear subfractions by western blotting. Mitf-M
indicated by triangle. (B and C) Graphic representation of Mitf and
fractions quantified by NIH Imaging J Version 1.62 software. (D) Dual
Note the strong expression of Rad6 in melanoma lines as compared
and localized to the cell membrane of HeMa-LP cells (arrow). Nucleapotential of the melanoma lines. Metastatic MDA-MB-231 human
breast cancer cells were used as a positive control. Consistent with the
lack of β-catenin transcriptional activity, normal HeMa-LP melano-
cytes failed to migrate, whereas all melanoma lines migrated/invaded
the Matrigel barrier (P b .001; Figure 1C). Interestingly, migratory
potentials correlated with Rad6 and modified β-catenin protein levels.
To further evaluate the functionality of β-catenin transcriptional
activity in melanoma lines, we analyzed the subcellular distributions
of β-catenin transcriptional targets Rad6 and Mitf in the cytoplasmic
and nuclear fractions of normal HeMa-LP and melanoma cells. Rad6
was detected in the cytoplasm of HeMa-LP and melanoma cells,
albeit at much higher levels in A2058, Mel-Juso, G361 and Malme-
3 M cells. Relative to the nuclear marker lamin A/C loading control,
normal HeMa-LP cells had negligible nuclear Rad6, whereas Rad6
was detectable in the nuclei of all melanoma lines (Figure 2A, and C).
Similar analysis of Mitf using a commonly used antibody that is not
selective to specific isoforms showed strong expression of Mitf-M (55-
60 kDa doublet indicated by open and closed circles in Figure 2A)
and lower levels of Mitf-A (indicated by the triangle in Figure 2A)a lines. (A) detection of Rad6, Mitf and Lamin A/C proteins in the
isoforms are indicated by open and closed circles, and Mitf-A is
Rad6 proteins levels, respectively, in the cytoplasmic and nuclear
immunofluorescence analysis of Rad6 (green) and β-catenin (red).
to normal HeMa-LP cells. Also note that β-catenin staining is weak
r localization of β-catenin in A2058 cells is indicated by an arrow.
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(Figure 2A). This pattern of Mitf-M and Mitf-A immunoreactive
bands detected by the clone C5Mitf antibody is consistent with those
described by Li et al. [39]. HeMa-LP cells showed only the Mitf-M
isoform in the nucleus, whereas A2058 cells showed similar
expression profiles of Mitf-M and Mitf-A in the cytoplasm and
nucleus (Figure 2A and B). Interestingly, nuclear Mitf was negligible
or very weakly detectable in A375, MelJuso and M14 cells, while
G361 and Malme-3 M cells had detectable but lower levels of nuclear
Mitf-M and Mitf-A compared to A2058 cells (Figure 2A). Consistent
with elevated β-catenin transcriptional activity in melanoma cell lines,
Rad6 was found to accumulate in both the cytoplasm and nucleus of
melanoma cells compared to normal melanocytes. However, since strong
expression of Mitf-M was detected in all cell lines including normal
HeMa-LP cells regardless of TOP/Flash activity, these findings suggest
that expression of Mitf-M is not dependent upon β-catenin activity.
Dual immunofluorescence staining of Rad6 and β-catenin were
performed to verify their presence and localization in normal HeMa-LP
and melanoma cells. HeMa-LP cells showed negligible Rad6
immunoreactivity, and β-catenin staining was localized to the cell
membranes (Figure 2D). In contrast, Rad6 and β-catenin staining was
intense in the melanoma lines. Consistent with TOP/Flash reporter
activity data, β-catenin was detected in the nuclei of all melanoma lines
with strongest nuclear β-catenin immunoreactivity in M14 and A2058
melanoma cells. Intense Rad6 staining was detected in the cytoplasm
that colocalized with β-catenin in the melanoma lines (Figure 2D).
Relevance of Rad6 in Clinical Melanoma
To analyze the potential role of Rad6 in melanoma development, we
evaluated expression of Rad6 and themelanocyte differentiation antigen
Melan-A in a melanoma tissue microarray by dual immunofluorescence
staining. The numbers of Rad6 positive andMelan-A positive cells were
scored, and Poisson regression analysis was applied to compare the
percentage of cells costaining for Rad6 andMelan-A in nevi vs. primary
cutaneous melanomas. The percent of Rad6 andMelan-A dual positive
cells ranged from 0% to 43.5% in the nevi group, and from 51.4% to
98.2% in the melanoma group. Limiting Rad6 expression analysis to
Melan-A positive cells could lead to underestimation of the number of
Rad6 positive cells in the tissue specimens as Melan-A is not uniformly
expressed in all nevi andmelanomas.However, comparison ofMelan- A
expression in nevi and melanoma samples have been shown to have
similar sensitivity and specificity values (75% to 92%, nevi vs. 95% to
100%, melanoma) [40]. Our data demonstrated that although the
number of cells positive for Melan-A was not significantly different
between the nevi and primary cutaneous melanoma groups (P = .5696),
histological diagnosis of melanoma was significantly associated with the
occurrence of Rad6/Melan-A dual positivity (P = .0029) with the odd
ratio of 1.98 (95% confidence interval 1.6-2.46) compared to the nevi
group. Also, compared to the nevi where only a few cell populations, if
any, showed Rad6 staining (Figure 3A), Rad6 was abundantly expressed
in malignant melanomas (Figure 3B). Similar analysis of Rad6 and β-
catenin in nevi and malignant melanomas by dual immunofluorescence
staining showed Rad6 and β-catenin costaining predominantly in
melanoma specimens. In malignant melanomas, β-catenin staining was
intense and widespread and colocalized with Rad6 (Figure 4). β-catenin
was localized on the cell membrane and cytoplasm of nevi and
melanomas, but was not found to localize in the nucleus. In rare cases
of nevi that showed Rad6 expression, Rad6 was present in the cytoplasm,
whereas in Rad6-positive melanomas, Rad6 was localized both inthe cytoplasm and nucleus (Figure 4). These data suggest that up-
regulation of Rad6 may play a role in the conversion of nevus to
cutaneous melanoma. The positive relationship between Rad6
expression and melanoma development was further verified in
superficial spreading malignant melanoma (SSMM) biopsies, the
most common form of cutaneous melanoma accounting for ~70%
of all diagnosed melanomas [41].
Expression and distribution of Rad6 and Melan-A, or Rad6 and β-
catenin in the normal adjacent and transformed areas of the same
specimen of SSMM were evaluated by double immunofluorescence
staining. Consistent with the maintenance of a stable ratio between
melanocytes and keratinocytes in the normal skin, few melanocytes,
as identified by Melan-A staining, were found in normal areas of the
skin. Rad6 expression was undetectable in these normal regions
(Figure 5A, panels a-a” and b-b”). Rad6 expression became noticeable
in the neighboring areas of skin that showed increased numbers of
(Melan-A positive) melanocytes (Figure 5A, panels c-c” and d-d”), and
Rad6 was overexpressed and colocalized with Melan-A stained cells in
tumor regions (Figure 5A, panels e-e”, f-f”). Similar analysis of Rad6 and
β-catenin showed an inverse relationship between Rad6 and β-catenin
in the normal areas of SSMM samples with strong β-catenin staining
and negligible Rad6 (Figure 5B, panels a-a”), whereas both Rad6 and β-
catenin staining were detected in the adjacent tumor areas (Figure 5B,
panels b-b”). These data suggest that unlike β-catenin, Rad6 may
contribute to the development of cutaneous melanoma.
Discussion
A major finding of this study is the discovery of Rad6 as an early marker
for cutaneous melanoma development.We show that Rad6, an ubiquitin
conjugating enzyme, and activator of canonical Wnt/β-catenin signaling
via β-catenin stabilizing modifications, plays an important role in
melanoma development. Analysis of clinical melanoma and nevi cores in
melanoma tissue microarray showed up-regulation of Rad6 expression in
primary melanoma cases compared to nevi. The present data are
supported by a detailed immunohistochemical study of Rad6 and β-
catenin in archived nevi, primary, andmetastaticmelanoma samples from
90 patients that showed Rad6 expression is associated with primary and
metastatic melanoma but not nevi, and that Rad6 that is overexpressed in
N95% ofmetastatic melanomas co-occurs with β-catenin in about half of
metastatic melanomas [42].
In support of the clinical data, western blot and immunofluorescence
analysis showed an inverse relationship between Rad6 and β-catenin in
normal melanocytes, whereas primary and metastatic melanoma cell
lines showed a direct correlation between levels of Rad6, highmolecular
weight β-catenin, β-catenin-mediated TOP/Flash reporter activity, and
migratory potential. These data are consistent with the positive feedback
loop between Rad6B gene expression and β-catenin stabilization/
activation reported in breast cancer, wherein Rad6B, a transcriptional
target of β-catenin, is induced by T-Cell factor/β-catenin [25], and
Rad6B in turn stabilizes β-catenin by inducing K63-linked poly-
ubiquitin modifications (high molecular weight β-catenin forms) that
bestow β-catenin with elevated transcriptional activity and resistance to
26S proteasomal degradation [24]. While the Rad6/β-catenin
connection is apparent in malignant melanoma cell lines, expression
of Mitf, also a transcriptional target of β-catenin [11], does not show a
similar association with the Wnt/β-catenin pathway as the melanocyte
specific Mitf isoform, Mitf-M, is abundantly expressed in normal
HeMa-LP melanocytes despite the absence of β-catenin mediated
TOP/Flash activity.Mitf-M is readily detectable in the nuclei of normal
Figure 3. Representative pictures of Rad6 and Melan-A staining detected by double immunofluorescence staining of nevi (A) and primary
melanomas (B) in melanoma tissue microarray. Original magnification, ×400.
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or lost from the nuclei of MelJuso, M14, G361 and Malme-3 M cells.
These data suggest that Mitf-M is necessary for the regulation of genes
required for the maintenance and differentiation of melanocytes, as
absence of Mitf-M in the nucleus is seen only in melanoma lines. The
Mitf gene is amplified in somemelanomas, and it has been suggested that
Mitf can function as a melanoma oncogene [43]. Mitf is down-regulated
in B-raf transformed murine melanocytes and B-raf overexpressinghuman melanocytes, and exogenous reexpression of Mitf inhibited the
proliferation of these cells [44]. These data suggest a tumor-suppressive
or differentiation-promoting role for Mitf in melanocytes. This role is
consistent with the function of Mitf in regulating cell cycle arrest via
activation of p21/WAF1 and p16Ink4a [45,46]. Since the melanoma
line A2058 shows abundant expression of Mitf-M and other Mitf
isoforms in the nucleus, this suggests that Mitf can support both
oncogenic and tumor suppressor functions. Cumulatively, these data
Figure 4. Representative pictures of Rad6 and β-catenin staining detected by double immunofluorescence staining of nevi and primary
melanomas in the melanoma tissue microarray. Panels a-a”’, staining in nevus, and panels b-b”’ and c-c”’, staining in malignant
melanomas. Original magnification, ×400.
Figure 5. Representative pictures of Rad6 and Melan-A (A) and Rad6 and β-catenin (B) staining detected by double immunofluorescence
staining of a representative superficial spreading malignant melanoma biopsy. (A) Note the absence of Rad6 in the normal areas (a-a”),
and its appearance that coincides with increases in Melan-A positive cells (b-b” to f-f”). Also note the presence of Rad6/Melan-A dual
positive cells in tumor areas (e-e” and f-f”). (B) Note the presence of β-catenin and absence of Rad6 in normal areas (a-a”) and
coexpression of Rad6 and β-catenin in the tumor regions of SSMM (b-b”). Original magnification, ×400.
390 Rad6 Role in Melanoma Pathogenesis Rosner et al. Translational Oncology Vol. 7, No. 3, 2014
Translational Oncology Vol. 7, No. 3, 2014 Rad6 Role in Melanoma Pathogenesis Rosner et al. 391suggest that Rad6 may be a more reliable marker than Mitf for
melanoma development.
Double labeling analysis of Rad6 and Melan-A, and Rad6 and
β-catenin in normal adjacent and transformed areas of the same
SSMM specimens shed further light on the significance of Rad6
as a potential early marker for neoplastic conversion to
melanoma. When melanocyte homeostasis is tightly regulated
by keratinocytes, a process occurring in normal skin, Rad6 is
undetectable. However, when homeostasis regulation is lost, as
evidenced by increases in the number of Melan-A positive cells,
Rad6 expression becomes noticeable. However, it is interesting to
note that Rad6 expression is not initially localized in melano-
cytes, but rather expressed in the neighboring keratinocytes,
prompting us to speculate that up-regulation of Rad6 in
neighboring cells likely plays a role in the deregulation of
melanocyte homeostasis and contributes to the risk of melanoma
development. This supposition is supported not only by
concurrent increases in the number of Melan-A positive cells,
but also by increases in Melan-A/Rad6 double positive cells in
tumor regions. Since the first detectable increase in Rad6
expression occurs in the neighboring keratinocytes that strongly express
β-catenin prompts us to speculate that Rad6 gene expression may be
induced by β-catenin, it’s transcriptional activator [25]. Double
immunofluorescence staining of Rad6 and β-catenin in SSMM samples
further confirmed the inverse and direct relationships between Rad6
and β-catenin expressions in the normal adjacent and tumor regions,
respectively, of SSMM, suggesting that Rad6 could be a goodmarker for
distinguishing benign nevi from melanoma.
Constantly elevated Rad6 expression in primary and metastatic
melanomas suggests that Rad6 may play an active role during all phases
of melanoma pathogenesis: initiation, maintenance and progression to
metastatic disease. It remains to be determined, however, whether the
melanoma transformation-inducing properties of Rad6 are solely
transmitted through β-catenin or through the function of Rad6 as a
postreplicationDNA repair protein. The postreplication repair pathway
enables completion of DNA replication blocked by damaging DNA
lesions via error-free and error-prone bypass mechanisms [18], and the
ubiquitin conjugating activity of Rad6 is critical to this process [47].
Since cells are challenged by environmental or endogenous processes
that induce DNA damage, we posit that the activation of Rad6
postreplication repair pathway in the early phase of melanoma
development may be necessary for ensuring completion of stalled
DNA replication and hence cell survival. Because postreplication
repair is often error prone or mutagenic, it is tempting to
speculate that Rad6 may participate in melanocyte transforma-
tion by directly contributing to genomic alterations underlying
melanoma pathogenesis.
In summary, our data suggest that Rad6 may serve as an early
marker for melanoma development. The first detectable increase in
Rad6 expression is correlated with melanocyte transformation, and is
further augmented in malignant melanoma, there by implicating
Rad6 as a novel anti-melanoma therapeutic target.
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